154 related articles for article (PubMed ID: 30358644)
1. Hibernoma as an incidental finding in the 18F-FDG PET/CT of a patient with melanoma.
Marcoval J; Sabaté-Llobera A; Bermejo J; Fornons-Servent R
Melanoma Res; 2020 Aug; 30(4):420-422. PubMed ID: 30358644
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC
Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029
[TBL] [Abstract][Full Text] [Related]
3. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
[TBL] [Abstract][Full Text] [Related]
4. Hibernoma: 18F FDG PET/CT imaging.
Subramaniam RM; Clayton AC; Karantanis D; Collins DA
J Thorac Oncol; 2007 Jun; 2(6):569-70. PubMed ID: 17545854
[TBL] [Abstract][Full Text] [Related]
5. Hibernoma as an incidental finding on (18)F-FDG-PET/CT in lymphoma patient follow-up.
Navarro-Pelayo MM; Rodríguez-Fernández A; Ramírez-Navarro Á; Martín-Castro A; Gómez-Río M; Llamas-Elvira JM
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):53-5. PubMed ID: 25982593
[No Abstract] [Full Text] [Related]
6. False-positive findings on 18F-FDG PET/CT: differentiation of hibernoma and malignant fatty tumor on the basis of fluctuating standardized uptake values.
Smith CS; Teruya-Feldstein J; Caravelli JF; Yeung HW
AJR Am J Roentgenol; 2008 Apr; 190(4):1091-6. PubMed ID: 18356460
[TBL] [Abstract][Full Text] [Related]
7. Propranolol 18F-FDG PET/CT: A Noninvasive Approach for Differential Diagnosis of Hibernoma and Liposarcoma.
Ciappuccini R; Bardet S; Aide N
Clin Nucl Med; 2017 Nov; 42(11):879-880. PubMed ID: 28902737
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Significance of Incidental Parotid Uptake in a PET/CT Study: A Diagnostic Algorithm.
Üstün F; Taştekin E; Taş A; Altun GD
Curr Med Imaging Rev; 2019; 15(3):326-333. PubMed ID: 31989884
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
11. [The role of preoperative (18)F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk].
Zhang XX; Fang Y; Xu LB; Xu SF; Zhao ZG; Sun C; Ma PQ; Liu T; Yu SJ; Zhang WJ
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):372-378. PubMed ID: 29860765
[No Abstract] [Full Text] [Related]
12. A Rare Case of Hibernoma Occasionally Identified by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in a Patient with Lung Cancer.
Penna D; Quartuccio N; Testa C; Arena V; Cistaro A; Pelosi E
Cureus; 2017 Mar; 9(3):e1124. PubMed ID: 28465871
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of 18F-FDG PET/CT lower-limb imaging in patients with malignant cutaneous melanoma.
Plouznikoff N; Arsenault F
Nucl Med Commun; 2017 Dec; 38(12):1103-1108. PubMed ID: 28885538
[TBL] [Abstract][Full Text] [Related]
14. Retrospective chart analysis of incidental findings detected by (18) F-fluorodeoxyglucose-PET/CT in patients with cutaneous malignant melanoma.
Conrad F; Winkens T; Kaatz M; Goetze S; Freesmeyer M
J Dtsch Dermatol Ges; 2016 Aug; 14(8):807-16. PubMed ID: 27509416
[TBL] [Abstract][Full Text] [Related]
15.
Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
[TBL] [Abstract][Full Text] [Related]
16. Fluorodeoxyglucose-PET in the management of malignant melanoma.
Kumar R; Mavi A; Bural G; Alavi A
Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645
[TBL] [Abstract][Full Text] [Related]
17. Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases.
Holtkamp LHJ; Chakera AH; Fung S; Stretch JR; Saw RPM; Lee K; Ch'ng S; Gonzalez M; Thompson JF; Emmett L; Nieweg OE
Melanoma Res; 2020 Aug; 30(4):358-363. PubMed ID: 32628431
[TBL] [Abstract][Full Text] [Related]
18. BSREM Reconstruction for Improved Detection of In-Transit Metastases With Digital FDG-PET/CT in Patients With Malignant Melanoma.
Aljared A; Alharbi AA; Huellner MW
Clin Nucl Med; 2018 May; 43(5):370-371. PubMed ID: 29485444
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
20. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Lee JW; Nam SB; Kim SJ
Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
